FDA Accepts Renewed Review of Troriluzole for Ataxia

Company Biohaven Event Type Regulatory: resubmission accepted Modality Small molecule (riluzole prodrug) Asset Troriluzole (Vyglxia) Target Glutamate modulation Disease Area Spinocerebellar ataxia Summary The FDA accepted Biohaven’s resubmitted troriluzole application for spinocerebellar ataxia and set a first-quarter 2027 review goal. This procedural advance reopens a…